Spots Global Cancer Trial Database for er
Every month we try and update this database with for er cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | NCT00073528 | Breast Neoplasm... | Lapatinib Letrozole Placebo | 18 Years - | Novartis | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | NCT02253238 | Head and Neck C... | Quality of Life... Health Manageme... Monitoring Devi... Symptoms Survey... Device Usabilit... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| 18-F-Fluoroacetate as PET Imaging Agent | NCT01320787 | Brain Cancer Breast Cancer Prostate Cancer | 18F-fluoroaceta... | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | NCT02253238 | Head and Neck C... | Quality of Life... Health Manageme... Monitoring Devi... Symptoms Survey... Device Usabilit... | 18 Years - | M.D. Anderson Cancer Center | |
| Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | NCT02253238 | Head and Neck C... | Quality of Life... Health Manageme... Monitoring Devi... Symptoms Survey... Device Usabilit... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women | NCT02214004 | Breast Cancer | Trastuzumab Letrozole | 18 Years - | Gangnam Severance Hospital | |
| Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women | NCT02214004 | Breast Cancer | Trastuzumab Letrozole | 18 Years - | Gangnam Severance Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
